Look out, Regeneron. As the threat from Roche's Vabysmo grows, one team of analysts...

[cafead]

via Regeneron's Eylea has long dominated the ophthalmology market thanks to its strong efficacy and safety profile. But its unquestioned run at the top now appears under threat.

article source